Latest News

Circassia Announces the Appointment of Dr James Shannon to its Board of Directors

06 January 2011

Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine

18 November 2010

Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for Cat Allergy T-cell Vaccine

Extended clinical portfolio now includes four mid-stage development programmes

30 September 2010

Circassia Announces Successful Phase II Study Meets Primary Endpoint and Extends Target Patient Population to Asthmatics for Cat Allergy T-Cell Vaccine

16 August 2010

Circassia Out-licenses ToleroTrans Organ Transplant Anti-Rejection Technology to Oxford Immunotec

12 August 2010

More recent news articles

Previous news articles

Did you know?

The average bed could be home to up to 1.5 million house dust mites